公开(公告)号：US11826376B2

公开(公告)日：2023-11-28

申请号：US16515086

申请日：2019-07-18

Applicant: AstraZeneca AB

Inventor： Anna Maria Langkilde

IPC: A61K31/70 ,  A61K45/06

CPC classification number: A61K31/70 ,  A61K45/06

Abstract: Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.

公开(公告)号：US12213988B2

公开(公告)日：2025-02-04

申请号：US17347230

申请日：2021-06-14

Applicant: ASTRAZENECA AB

Inventor： Anna Maria Langkilde

IPC: A61K31/7004 ,  A61K9/00 ,  A61K31/351 ,  A61K31/401 ,  A61K31/41 ,  A61K31/4178 ,  A61K45/06 ,  A61P13/12

Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

公开(公告)号：US11903955B2

公开(公告)日：2024-02-20

申请号：US17184746

申请日：2021-02-25

Applicant: ASTRAZENECA AB

Inventor： Anna Maria Langkilde

IPC: A61P9/04 ,  A61K31/351 ,  A61K31/70

CPC classification number: A61K31/70 ,  A61K31/351 ,  A61P9/04

Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.

公开(公告)号：US10973836B2

公开(公告)日：2021-04-13

申请号：US16812745

申请日：2020-03-09

Applicant: ASTRAZENECA AB

Inventor： Anna Maria Langkilde

IPC: A61P9/04 ,  A61K31/351 ,  A61K31/70

Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.